AlphAIalphai — Financial news for AI agents
financialcontent.comAUG 114 min read$STAA

What To Expect From STAAR Surgical’s (STAA) Q2 Earnings

STAAR Surgical (NASDAQ: STAA) is set to report Q2 earnings Wednesday after market close. The company’s prior quarter revenue was $93.52 million, up 120% year over year. For the upcoming quarter, analysts expect revenue to rise 104% year over year. The article cites an average analyst price target of $28.70 versus a $25.31 share price.

Original reporting
financialcontent.com
Published Aug 11, 2026, 3:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 4:08 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
What To Expect From STAAR Surgical’s (STAA) Q2 Earnings — source image
Source · financialcontent.com
Decision brief

The 30-second read

$STAANeutralMed
01

Why it matters

Traders can use the stated consensus revenue growth (104% YoY) and the company’s recent revenue-estimate miss history to frame expectations for the after-hours print and potential guidance sensitivity.

02

Market read

This is a pre-earnings positioning brief for STAA, anchored to consensus revenue growth and peer read-through rather than new company disclosures.

03

What to watch

The preview focuses on revenue growth expectations but does not provide margin, cash flow, or product-specific drivers that often determine post-earnings repricing.

Relevance 4/10Novelty 3/10Timing: ahead of Wednesday after-hours Q2 earnings

Background

STAAR Surgical is scheduled to report Q2 earnings after market hours Wednesday; the article contrasts last quarter’s strong beat with the current quarter’s consensus growth expectation.

Company-level read

Ticker impact

$STAANeutralMedium confidence
Context

Article previews STAAR Surgical’s Q2 earnings after-hours Wednesday, citing consensus revenue growth expectations and recent estimate reconfirmations.

Expected impact

Near-term volatility likely around the after-hours Q2 print versus the stated revenue growth expectation and the company’s history of missing revenue estimates.

Evidence & confidence

No new earnings numbers or guidance are disclosed here; the actionable element is the market’s expectation (104% YoY revenue growth) and the framing of recent estimate behavior and peer results.

Market effects

Sector

Peer Q2 results in medical devices and supplies, specialty are used as a read-through for the segment’s near-term sentiment.

Regional

None specified.

Global

None specified.

Counterpoint

What could challenge this read

Peer beats and segment optimism may not translate to STAA given the article’s note that STAA has missed revenue estimates multiple times over two years.

Key entities

  • company
    STAAR Surgical

    NASDAQ-listed medical lens company scheduled to report Q2 earnings after market hours Wednesday.

  • company
    Inspire Medical Systems

    Peer cited as having reported Q2 revenue down 7.6% YoY but beating expectations, with shares up 22.8%.

  • company
    Integer Holdings

    Peer cited as having reported Q2 revenue down 2.6% YoY but topping estimates, with shares up 3.2%.

Read at source← All news

Related articles

AUG 20
$STAAHighAI 8/10

STAAR (STAA) Q2 2026 Earnings Call Transcript

STAAR Surgical (STAA) reported Q2 2026 net sales of $93.5M, up 111% YoY, driven by China and Americas growth. Net income was $8.1M, or $0.16 per share, with adjusted EBITDA at $20.0M. Gross margin improved to 74.5%. Management highlighted EVO Plus success in China and U.S. market share gains, but noted risks from China tariffs and supply chain constraints.

fool.com3 min
AUG 17
$STAAMed

Why STAAR Surgical (STAA) Shares Are Sliding Today

STAAR Surgical (STAA) shares fell about 8% after Q2 results and sentiment cooled. The company reported sales and EPS above analysts’ estimates but cited uneven refractive market conditions and ongoing tariff and currency headwinds, especially in Asia. Stifel cut its price target to $28 from $31 (Hold) due to concerns about China. Shares closed at $24.15.

financialcontent.com4 min
AUG 12
$STAAMedAI 8/10

STAAR SURGICAL CO (STAA): Results of Operations and Financial Condition

STAAR SURGICAL CO (STAA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 staa-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 STAAR Surgical Reports Second Quarter 2026 Results Net Sales of $93.5 million, up 111% Y/Y Net Income of $8.1 million, with GAAP EPS of $0.16 Adjusted EBITDA 1 of $20.0 million, or $0.39 per diluted share Earnings Call and We

SEC EDGAR 8-K6 min